



SUVEN LIFE SCIENCES LTD

Regd. Off: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad - 500 034
Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 email: investorservices@suvan.com website: www.suvan.com CIN: L24110TG1989PLC009713

STATEMENT OF UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER & HALF-YEAR ENDED 30th SEPT' 2018

All amounts in Indian Rupees in Lakhs

Sl. No.	Particulars	For the Quarter Ended			For the 6 Months Ended		For the year Ended
		30-Sep-2018	30-Jun-2018	30-Sep-2017	30-Sep-2018	30-Sep-2017	31-Mar-2018
		Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1	Income						
	Revenue from operations	8,952.18	19,166.22	10,685.88	28,118.40	24,787.78	62,525.84
	Other Income	658.63	812.77	513.23	1,471.40	1,075.52	2,327.07
	Total income	9,610.81	19,978.99	11,199.11	29,589.80	25,863.30	64,852.91
2	Expenses						
	a) Cost of materials consumed	4,102.39	3,859.30	4,218.13	7,961.69	7,901.66	17,490.30
	b) Purchases of stock-in-trade	-	-	-	-	-	-
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(3,525.10)	2,595.82	(3,189.36)	(929.28)	(3,416.53)	(2,120.13)
	d) Employee benefits expense	1,398.33	1,714.82	1,267.76	3,113.15	2,833.98	5,873.50
	e) Finance costs	59.09	106.79	93.58	165.88	220.59	461.11
	f) Depreciation and amortisation expense	556.05	550.81	533.99	1,106.86	1,053.19	2,130.99
	g) Manufacturing Exps	2,493.06	2,285.50	2,101.03	4,778.56	4,291.40	8,821.54
	h) R & D Exps	1,238.73	1,598.87	1,166.13	2,837.60	2,767.32	5,846.66
	i) Other Expenses	803.29	1,288.81	622.66	2,092.10	1,381.72	3,322.37
	Total expenses	7,125.84	14,000.72	6,813.92	21,126.56	17,033.33	41,826.34
3	Profit before exceptional items & Tax (1-2)	2,484.97	5,978.27	4,385.19	8,463.24	8,829.97	23,026.57
4	Exceptional Items	-	-	-	-	-	-
5	Profit before Tax (3-4)	2,484.97	5,978.27	4,385.19	8,463.24	8,829.97	23,026.57
6	Tax Expenses						
	a) Current tax	513.83	1,249.14	592.11	1,762.97	1,724.88	4,756.49
	b) Deferred tax	170.17	844.92	618.35	1,015.09	973.29	2,427.35
7	Net Profit/ (Loss) for the period/year(5-6)	1,800.97	3,884.21	3,174.73	5,685.18	6,131.80	15,842.73
8	Other Comprehensive Income						
8.a	(i) Items that will not be reclassified to profit or loss	(10.59)	(10.58)	(3.72)	(21.17)	(7.45)	(42.33)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	3.67	3.66	1.29	7.33	2.58	14.65
8.b	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other Comprehensive Income	(6.92)	(6.92)	(2.43)	(13.84)	(4.87)	(27.68)
9	Total Comprehensive Income for the period (7+8)	1,794.05	3,877.29	3,172.30	5,671.34	6,126.93	15,815.05
10	Paid-up equity share capital (face value of Rs. 1/- each)	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82	1,272.82
11	Other Equity						85,397.16
12	Earning Per Share (EPS) (Face value of Rs.1/- each)						
	a) Basic	1.41	3.05	2.49	4.47	4.82	12.45
	b) Diluted	1.41	3.05	2.49	4.47	4.82	12.45
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	

SEGMENT WISE REVENUE, RESULTS AND TOTAL ASSETS AND LIABILITIES

PARTICULARS	For the Quarter Ended			For the 6 Months Ended		For the year Ended
	30-Sep-2018	30-Jun-2018	30-Sep-2017	30-Sep-2018	30-Sep-2017	31-Mar-2018
	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Un-Audited	Audited
1 SEGMENT REVENUE :-						
a) Manufaturing (CRAMS)	8,087.96	18,024.22	10,026.47	26,112.18	23,357.23	59,687.64
b) Services (DDDSS)	864.22	1,142.00	659.41	2,006.22	1,430.55	2,838.20
c) Research & Development	-	-	-	-	-	-
TOTAL	8,952.18	19,166.22	10,685.88	28,118.40	24,787.78	62,525.84
Less Inter segment Revenue	-	-	-	-	-	-
Net Sales from Operations	8,952.18	19,166.22	10,685.88	28,118.40	24,787.78	62,525.84
2 SEGMENT RESULTS :-						
Profit/(Loss) before tax and interest:						
a) Manufaturing (CRAMS)	3,252.05	7,086.74	5,312.13	10,338.79	11,094.99	28,031.87
b) Services (DDDSS)	440.55	761.15	319.36	1,201.70	724.61	1,428.77
c) Research & Development	(1,238.71)	(1,598.88)	(1,166.14)	(2,837.59)	(2,767.32)	(5,846.66)
TOTAL	2,453.89	6,249.01	4,465.35	8,702.90	9,052.28	23,613.98
Less: i) Interest	62.29	35.97	74.19	98.26	161.30	281.59
ii) Other Un-allocable expenditure/(Income), net	(93.37)	234.77	5.97	141.40	61.01	305.82
Total Profit Before Tax	2,484.97	5,978.27	4,385.19	8,463.24	8,829.97	23,026.57
3 SEGMENT ASSETS :						
a) Manufaturing (CRAMS)	57,618.63	48,587.81	53,711.58	57,618.63	53,711.58	52,557.03
b) Services (DDDSS)	3,767.31	4,339.17	4,077.86	3,767.31	4,077.86	4,061.14
c) Research & Development	3,028.20	2,784.33	2,896.37	3,028.20	2,896.37	3,031.96
d) Un allocated	44,219.74	50,187.02	35,647.25	44,219.74	35,647.25	41,234.30
TOTAL	108,633.88	105,898.33	96,333.06	108,633.88	96,333.06	100,884.43
SEGMENT LIABILITIES :						
a) Manufaturing (CRAMS)	9,282.73	9,053.42	9,984.93	9,282.73	9,984.93	8,594.07
b) Services (DDDSS)	473.46	315.25	574.83	473.46	574.83	382.64
c) Research & Development	1,669.94	1,323.46	2,253.38	1,669.94	2,253.38	1,587.28
d) Un allocated	949.14	867.09	925.47	949.14	925.47	714.79
TOTAL	12,375.27	11,559.22	13,738.61	12,375.27	13,738.61	11,278.78

1). The above financial results were reviewed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 14th November, 2018 and the same reviewed by the Statutory Auditors.

2). Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.

3). The corresponding previous period figures have been regrouped / reclassified where ever necessary.

For SUVEN LIFE SCIENCES LIMITED

Place: Hyderabad
Date: 14th November, 2018

VENKAT JASTI
Chairman & CEO
DIN: 00278028

We Deliver

**SUVEN LIFE SCIENCES LTD**

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, 500 034, Telangana, India. CIN: L24110TG1989PLC009713

Statement of Assets & Liabilities

	Particulars	Standalone as at	
		30/09/2018	31/03/2018
A	ASSETS		
1	Non-current assets		
	(a) Property, Plant and Equipment	29,724.69	30,494.25
	(b) Capital Work-in-Progress	5,869.68	2,474.38
	(c) Other Intangible Assets	265.42	278.31
	(d) Financial Assets		
	I. Investments	11,570.19	10,229.64
	II. Loans	6.34	3.79
	III. Other Financial Assets	609.00	610.53
	(e) Deferred tax assets (net)	-	-
	(f) Other non current assets	3,384.33	1,259.73
	Total Non-Current assets	51,429.65	45,350.63
2	Current assets		
	(a) Inventories	14,000.91	13,946.62
	(b) Financial Assets		
	I. Investments	29,645.49	27,872.56
	II. Trade Receivables	6,261.06	6,153.81
	III. Cash and Cash equivalents	1,099.70	1,342.59
	IV. Bank balances other than (III) above	46.04	51.12
	V. Loans	14.78	10.20
	VI. Other Financial assets	0.28	0.28
	(c) Current Tax asset (net)	912.06	340.34
	(d) Other current assets	5,223.91	5,816.28
	Total Current assets	57,204.23	55,533.80
	TOTAL - ASSETS	108,633.88	100,884.43
B	EQUITY AND LIABILITIES		
1	EQUITY		
	(a) Equity Share Capital	1,272.82	1,272.82
	(b) Other Equity	91,068.49	85,397.16
	Equity attributable to owners of the company	92,341.31	86,669.98
2	LIABILITIES		
	(a) Financial Liabilities		
	I. Borrowings	113.16	138.52
	(b) Provisions	382.44	368.68
	(c) Other non current liabilities	90.23	104.76
	(d) Deferred tax Liabilities (net)	3,331.47	2,323.71
	Total non-current liabilities	3,917.30	2,935.67
	Current liabilities		
	(a) Financial Liabilities		
	I. Borrowings	3,075.33	2,494.19
	II. Trade payables		
	a) To Micro & Small Enterprises	-	-
	b) Other than Micro & Small Enterprises	4,372.13	5,681.58
	III. Other Financial Liabilities	3,430.46	1,587.68
	(b) Other Current liabilities	948.59	1,041.32
	(c) Provision Employee benefits	548.76	474.01
	Sub-total - Current liabilities	12,375.27	11,278.78
	Total Liabilities	16,292.57	14,214.45
	TOTAL - EQUITY AND LIABILITIES	108,633.88	100,884.43

For Suven Life Sciences Ltd

Venkat Jasti
Chairman & CEO